179 related articles for article (PubMed ID: 27745917)
1. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
2. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
4. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
[TBL] [Abstract][Full Text] [Related]
5. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
Liu Z; Qi S; Zhao X; Li M; Ding S; Lu J; Zhang H
Oncotarget; 2016 Apr; 7(16):21315-31. PubMed ID: 26824324
[TBL] [Abstract][Full Text] [Related]
8. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
[TBL] [Abstract][Full Text] [Related]
9. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
10. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
Bateman NW; Teng PN; Hope E; Hood BL; Oliver J; Ao W; Zhou M; Wang G; Tommarello D; Wilson K; Litzy T; Conrads KA; Hamilton CA; Darcy KM; Casablanca Y; Maxwell GL; Bae-Jump V; Conrads TP
Cancer Med; 2020 Feb; 9(3):1092-1103. PubMed ID: 31808620
[TBL] [Abstract][Full Text] [Related]
11. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Kitson SJ; Maskell Z; Sivalingam VN; Allen JL; Ali S; Burns S; Gilmour K; Latheef R; Slade RJ; Pemberton PW; Shaw J; Ryder WD; Kitchener HC; Crosbie EJ
Clin Cancer Res; 2019 Apr; 25(8):2424-2432. PubMed ID: 30563932
[TBL] [Abstract][Full Text] [Related]
12. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
13. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.
Pabona JMP; Burnett AF; Brown DM; Quick CM; Simmen FA; Montales MTE; Liu SJ; Rose T; Alhallak I; Siegel ER; Simmen RC
Reprod Sci; 2020 Jan; 27(1):267-277. PubMed ID: 32046384
[TBL] [Abstract][Full Text] [Related]
14. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
15. The use of an immunocytochemical double-labeling staining can display the distribution of Bcl-2/Ki-67 cells in endometrial adenocarcinomas as well as in normal endometrium.
Mourtzikou A; Kosmas K; Marouga A; Stamouli M; Pouliakis A; Karakitsos P
Clin Lab; 2012; 58(1-2):133-44. PubMed ID: 22372356
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052
[TBL] [Abstract][Full Text] [Related]
17. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.
Bogusiewicz M; Semczuk A; Gogacz M; Skomra D; Jakowicki JA; Rechberger T
Cancer Lett; 2006 Jul; 238(1):61-8. PubMed ID: 16085355
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
Zou J; Hong L; Luo C; Li Z; Zhu Y; Huang T; Zhang Y; Yuan H; Hu Y; Wen T; Zhuang W; Cai B; Zhang X; Huang J; Cheng J
Cancer Sci; 2016 Dec; 107(12):1806-1817. PubMed ID: 27636742
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]